Sunday 18 October 2026 Export NUWE’s income statement to Excel — free account

Nuwellis, Inc.

Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.

0.55 0.00 0.00%

Follow NUWE

Alert me

Market cap: $2.0M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 3/9
Altman Z: −76.39
Beneish M: −7.71
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.01

Revenue 9.01

Net Income (11.32)

Free Cash Flow (12.68)

Net Debt (3.92)

Current Ratio 1.97

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.07)

P/S ratio 0.01

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 92.50%

Next Y EPS Growth 72.49%

Next Y revenue growth 19.32%

Next 5Y EPS Growth 85.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.14%

10-year low 10-year high

EV/Sales against its own 10 years 0.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	1	4
Receivables	2	2	1	2
Inventory	2	2	2	2
Other	0	0	1	1
	8	9	5	8

	2023	2024	2025	Q'26
Payables	2	2	2	3
ST’ Debt	—	—	—	—
Other	0	0	0	0
	3	3	3	4

Compound Annual Growth %

	10y	5y	3y
Sales	63.93%	2.14%	(1.08%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.20%)	(30.58%)	(40.29%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	2	—	—	—
’25	2	2	2	2	8
’24	2	2	2	2	9
’23	2	2	2	3	9
’22	2	2	2	2	9
’21	2	3	2	2	8
’20	2	2	2	2	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(3)	(3)	(11)
’24	(3)	(3)	(2)	(2)	(10)
’23	(6)	(5)	(4)	(3)	(18)
’22	(5)	(4)	(3)	(3)	(15)
’21	(5)	(4)	(4)	(4)	(18)
’20	(5)	(3)	(4)	(3)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(3)	(3)	(11)
’24	(3)	(3)	(2)	(2)	(10)
’23	(6)	(5)	(4)	(3)	(18)
’22	(5)	(4)	(3)	(3)	(15)
’21	(5)	(4)	(5)	(4)	(18)
’20	(6)	(3)	(5)	(3)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(73.08)	(26.64)	—	—	—
’25	(1.01k)	(2.13k)	19.58	(52.45)	(887.76)
’24	(35.42k)	(27.69k)	402.75	(646.41)	(12.36k)
’23	(295.88k)	(187.49k)	(92.98k)	(115.06k)	(591.76k)
’22	(2.16m)	(2.11m)	(1.90m)	(256.84k)	(4.29m)
’21	(1.61)	(0.72)	(0.74)	(2.11m)	(14.74m)
’20	(57.08m)	(3.10)	(2.08)	(5.80m)	(9.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	194,480,996,352.00	6,201,782,784.00	864,360,000.00	92,610,000.00	29,841,000.00	5,505,150.00	312,816.00	21,094.50	1,352.40	59.85	Analyst estimates 2026–2028 Powerpack
	High	2,100,394,852,352.00	518,615,990,272.00	10,372,320,256.00	2,145,464,960.00	199,111,504.00	63,695,100.00	9,518,250.00	615,342.00	44,247.00	2,454.90
People
People	Employees	29	46	55	32	30	70	70	59	19	24
	Revenue/emp, $m	0.04	0.08	0.09	0.17	0.25	0.11	0.12	0.15	0.46	0.34
Income, $m
Income, $m	Revenue	1	4	5	6	7	8	9	9	9	8
	Gross margin, %	44.69	22.23	26.57	51.73	54.52	56.70	55.66	56.22	64.94	61.96
	EBT	(16)	(13)	(17)	(18)	(16)	(20)	(15)	(20)	(11)	(18)
	EBT margin, %	(1,229.33)	(376.47)	(340.66)	(328.54)	(212.70)	(246.75)	(169.92)	(227.90)	(127.69)	(211.80)
	Net income	(16)	(13)	(17)	(18)	(16)	(20)	(15)	(20)	(11)	(18)
	Depreciation	1	5	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	39.06	74.02	12.37	68.04	4.51	0.00	0.00	0.00	9,711.11	419.80
	Earnings	(478.55)	—	(42.16)	—	(9.60)	(14,742,560.00)	(4,291,780.00)	(591,757.10)	(12,355.29)	(887.76)
	Cash flow	(493.70)	(248.33)	(36.04)	(202.06)	(10.05)	0.00	0.00	0.00	(10,656.67)	(548.73)
	Capex	(3.55)	(5.40)	(0.49)	(6.05)	(0.16)	0.00	0.00	0.00	(66.67)	(4.57)
	Free cash flow	(497.24)	(253.73)	(36.53)	(208.11)	(10.21)	0.00	0.00	0.00	(10,723.33)	(553.30)
	Book value	67.94	338.29	14.69	24.57	9.90	0.00	0.00	0.00	7,255.56	133.50
	Shares, m	0	0	0	0	2	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	9,819,696,209.25	103,927,553.22	85,588,590.18	1,951,010.89	7,947,078.16	0.00	0.00	0.00	0.17	0.15
	P/B	8,523,071,553.27	22,740,152.52	72,063,978.05	5,403,025.63	3,623,863.74	0.00	0.00	0.00	0.23	0.46
	EV/Sales	9,819,696,212.25	103,927,550.50	85,588,590.26	1,951,011.42	7,947,076.75	(2.56)	(1.68)	0.02	0.04	0.49
	EV/FCF	(912,611,172.14)	(30,301,541.68)	(28,985,755.12)	(637,837.33)	(3,511,740.49)	1.12	0.94	(0.01)	(0.03)	(0.37)
Cash, $m
Cash, $m	Operating cash flow	(16)	(12)	(15)	(16)	(17)	(18)	(15)	(18)	(10)	(11)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(16)	(12)	(15)	(17)	(17)	(18)	(15)	(18)	(10)	(11)
Balance, $m
Balance, $m	Working capital	(1)	16	5	1	15	25	18	5	6	2
	Total debt	—	—	—	0	0	0	1	—	—	—
	Net debt	(1)	(16)	(5)	(1)	(14)	(24)	(18)	(4)	(5)	(1)
	Shareholders’ equity	2	16	6	2	16	26	12	3	7	3
Returns, %
Returns, %	ROA	(110.85)	(192.64)	(125.09)	(314.69)	(137.37)	(77.55)	(52.73)	(131.39)	(108.22)	(219.21)
	ROIC	(1,065.15)	(1,439.74)	(2,334.98)	(1,164.22)	(550.00)	(689.48)	0.00	0.00	(478.57)	(449.27)
	ROE	(254.05)	(277.54)	(153.62)	(570.86)	(192.19)	(92.53)	(75.84)	(294.87)	(223.24)	(382.80)

Negative figures in brackets.

value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADGM Adagio Medical Holdings, Inc.	$2.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
NXL Nexalin Technology, Inc.	$2.6M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)	Compare
BIOLQ Biolase, Inc.	$2.3M	— (loss-making)	— (loss-making)	−0.65% (below 0%: shrinking)	n/m	−60.22% (below 0%: shrinking)	40.39%	(6.41%)	Compare
XAIR Beyond Air, Inc.	$2.2M	— (loss-making)	— (loss-making)	+0.45% (above 0%: growing)	n/m	−9.10% (below 0%: shrinking)	12.73%	(373.98%)	Compare
NUVOQ Holdco Nuvo Group D.G Ltd.	$2.1M	— (loss-making)	—	—	n/m	−1.05% (below 0%: shrinking)	0.00%	0.00%	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
Median of peers	$2.2M	—	—	−0.65%	—	−19.78%	13.47%	(20.01%)

All 149 Medical Devices stocks →

Nuwellis, Inc. (NUWE) key facts

Concern: Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024.
Nuwellis, Inc. (NUWE) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NUWE traded at $0.55, a market capitalization of $2.0 million.
Return on equity was −382.8% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −76.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.